InClinica CEO Speaks at the 2nd World Congress on Clinical Trials in Diabetes in Berlin
James Nolan provided industry professionals guidance on selecting a CRO and an IP attorney
PHILADELPHIA (November 29, 2017) – InClinica, a global, clinical CRO, announced that CEO James Nolan presented two special lectures at the 2nd World Congress on Clinical Trials in Diabetes on Monday, November 27 and Tuesday, November 28 in Berlin, Germany.
Nolan’s lectures, titled “The Importance of IP and How to Select the Right Attorney and Firm” and “How to Pick and Qualify a CRO,” addressed the best ways for companies to navigate the decision process when choosing clinical and legal support for their clinical trial. He highlighted how the trust between a company, attorney, and CRO is integral to a trial’s success.
“To ensure the highest probability for success in a trial, companies must consider all their options when selecting a CRO and attorney,” said Nolan. “While they serve different purposes, it’s important to find people in both fields who understand the best way to serve the trial’s needs in a competitive and evolving landscape. A trial will be a no go from the start if it is not supported by professionals who will treat the trial as if it was their own creation.”
The World Congress on Clinical Trials in Diabetes focuses on designing studies that yield the highest probability of achievement and high-quality data – while at the same time trying to improve the regulatory process and incorporate digital medical advancements. The World Congress brings together researchers, clinicians, industry professionals and other related experts to look at ways of improving trials from patient recruitment and retention to design elements that will create the highest probability of success. For more information, visit: http://www.wctd2017.com/default.aspx.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in Israel, Malaysia/Singapore, the U.K., and throughout Europe.